In the hormone-dependent prostate inflammation model induced by implantation of slow-releasing pellets (50 mg testosterone and 5 mg estradiol) to Noble male rats, intragastric administration of Afala at a dose of 7.5 ml/kg for 18 weeks reduced the number of inflamed prostatic acini. The effect of afala was comparable with that of antiestrogen ICI 182,780 (3 mg/kg subcutaneously twice a week for 18 weeks). Prolonged treatment with hormones in high doses induced severe inflammation of the prostate tissue, which was not terminated by the test preparations. As differentiated from the antiestrogen ICI 182,780, afala did not induce body weight gain and decrease in pituitary weight in experimental animals in comparison with the control group.

01 Aug 2009·Bulletin of Experimental Biology and MedicineQ4 · MEDICINE

Clinical Study of the Efficiency and Safety of Afala in Patients with Benign Prostatic Hyperplasia

Q4 · MEDICINE

Article

Author: R. A. Kazikhinurov ; K. V. Savel’eva ; V. V. Udut ; S. A. Sergeeva ; Yu. L. Dugina ; A. B. Mukhin ; Z. A. Yurmazov ; M. Yu. Frolov ; V. N. Pavlov ; M. V. Kachanova ; O. I. Epshtein

The use of afala in patients with benign prostatic hyperplasia and moderate urination disturbances reduced the symptoms of the disease, improved urodynamic parameters, and increased quality of life. Clinical efficiency of afala was comparable with the efficiency of Serenoa repens extract (reference preparation).

01 Aug 2009·Bulletin of Experimental Biology and MedicineQ4 · MEDICINE

Efficiency of Afala in Complex Therapy of Patients with Chronic Prostatitis

Q4 · MEDICINE

Article

Author: Kul'chavenya, E V

The use of afala in complex treatment of patients with chronic prostatitis improves the efficiency of therapy and prolongs its positive results. The preparation is well tolerated, has no contraindication, and can be combined with other drugs. Afala is indicated for patients with stages II and IIIa chronic prostatitis from the first day of therapy.

100 Deals associated with Afala

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Prostatic Cancer	Russia	Materia Medica Holding Research And Production Company	01 Jan 2014
Prostatitis	Russia	Materia Medica Holding Research And Production Company	01 Jan 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis